Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

By M. Schrappe, A. Reiter, W. Ludwig, J. Harbott, M. Zimmermann, W. Hiddemann, C. Niemeyer, G. Henze, A. Feldges, F. Zintl and 5 more. Blood, 2000

695 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. (2002, background): “By tailoring the intensity of treatment to a patient’s relative risk of relapse, patients are neither underment protocols achieving overall long-term event-free survival rates approaching 80% (Schrappe et al., 2000; Silverman et al., treated or overtreated and are thus afforded the highest chance fo”
High expression of precursor microRNA‐155/BIC RNA in children with Burkitt lymphoma (2004, background): “The BIC locus was originally identified as a common retroviral integration site in avian-leukosis virus–induced B–cell lymphomas (Clurman and Hayward, 1989; Tam et al., 1997).”
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. (2003, neutral): “9 [1-458] 15.”
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia (2004, neutral): “Age (yrs) 40 147 (51) 40–59 82 (28) 60 59 (20) Performance score (ECOG scale) 3–4 19 (7) Splenomegaly Yes 76 (26) Hepatomegaly Yes 44 (15) Lymphadenopathy Yes 91 (32) CNS disease at diagnosis Yes 19 (7) Mediastinal mass Yes 20 (7) Leukocyte count ( 10(9)/L) 5 105 (36) 5–49 135 (47) 50 48 (17) Platel”